SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
LEBEL FRANCOIS

(Last) (First) (Middle)
11500 S. EASTERN AVE., SUITE 240

(Street)
HENDERSON NV 89052

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SPECTRUM PHARMACEUTICALS INC [ SPPI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/19/2019
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.001 par value 06/19/2019 A 50,000(1) A $0.00 120,250 D
Common Stock, $0.001 par value 948 I By 401(k) plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $8.48 06/19/2019 A 125,000 (2) 06/19/2029 Common Stock 125,000 $0.00 50,000 D
Explanation of Responses:
1. One third of the aggregate amount of restricted shares shall vest on each of June 19, 2020, 2021 and 2022, respectively.
2. 25% of the option shares vested on June 19, 2019. The remaining option shares shall vest in 25% equal annual amounts on each anniversary date of the grant over three years.
Remarks:
/s/ Kurt A. Gustafson, attorney-in-fact for Francois Lebel 06/21/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
POWER OF ATTORNEY
AUTHORIZATION

I hereby authorize Joseph W. Turgeon, Kurt A. Gustafson and Keith McGahan,
acting singly, to sign and file on my behalf any and all forms required by 
the Securities and Exchange Commission pursuant to Section 16 of the 
Securities Exchange Act of 1934 (the "Exchange Act") relating to the 
reporting of beneficial ownership of equity securities of Spectrum 
Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and 
of changes in such beneficial ownership, together with any and all 
amendments thereto.  This authorization shall be effective on and 
after the date set forth below and shall continue in effect until 
I am no longer required to file such forms, unless earlier revoked
by me in writing.

I acknowledge that the persons authorized hereunder are not assuming, 
nor is the Company assuming, any of my responsibilities to comply 
with Section 16 of the Exchange Act.

Dated as of this 5th day of March 2019.

/s/ Francois Lebel, M.D.
 Francois Lebel, M.D.